We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Gives Complete Response to J&J’s Simponi sBLA
FDA Gives Complete Response to J&J’s Simponi sBLA
July 29, 2011
Johnson and Johnson (J&J) subsidiary Janssen Biotech has received a complete response letter for its Simponi sBLA, intended to expand the inflammatory disease drug’s label to include inhibiting the progression and maintenance of reduction of signs and symptoms of rheumatoid arthritis (RA).